Cargando…

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid

BACKGROUND: Bempedoic acid (BA) inhibits ATP‐citrate lyase in the cholesterol synthesis pathway and lowers low‐density lipoprotein cholesterol (LDL‐C). As with other lipid‐lowering therapies, interindividual variation in response to BA was observed in clinical trials. We characterized LDL‐C response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballantyne, Christie M., Bays, Harold E., Louie, Michael J., Smart, Jeremy, Zhang, Yang, Ray, Kausik K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375471/ https://www.ncbi.nlm.nih.gov/pubmed/35916348 http://dx.doi.org/10.1161/JAHA.121.024531

Ejemplares similares

Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Correction to: Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
por: Bays, Harold E., et al.
Publicado: (2021)

Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
por: Pradhan, Akshyaya, et al.
Publicado: (2023)

Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
por: Gunn, Laura H., et al.
Publicado: (2022)

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
por: Bays, Harold E
Publicado: (2014)

Bempedoic Acid’s Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review
por: Goit, Raman, et al.
Publicado: (2022)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia
por: Jadhav, Satyawan B., et al.
Publicado: (2023)

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016)

An Update on New Cholesterol Inhibitor: Bempedoic Acid
por: Kulshreshtha, Mayank
Publicado: (2022)

THU584 Comparison Of The Cardiovascular Benefits Of Bempedoic Acid With Statins- Analysis By The Cholesterol Treatment Trialists’ Methodology
por: Lincoff, A Michael, et al.
Publicado: (2023)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
por: Tummala, Ramyashree, et al.
Publicado: (2022)

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
por: Szarek, Michael, et al.
Publicado: (2020)

Low-density lipoprotein cholesterol lowering treatment: the current approach
por: Crismaru, Irina, et al.
Publicado: (2020)

Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
por: Jialal, Ishwarlal, et al.
Publicado: (2023)

Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Statins and Bempedoic Acid: Different Actions of Cholesterol Inhibitors on Macrophage Activation
por: Linnenberger, Rebecca, et al.
Publicado: (2021)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital
por: Nanda, Sunil Kumar, et al.
Publicado: (2017)

Isolated low levels of high‐density lipoprotein cholesterol and stroke incidence: JMS Cohort Study
por: Watanabe, Jun, et al.
Publicado: (2019)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome
por: Biswas, Hope H., et al.
Publicado: (2015)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
por: Bardolia, Chandni, et al.
Publicado: (2021)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis
por: Chen, Suet Nee, et al.
Publicado: (2009)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
por: Colhoun, Helen M., et al.
Publicado: (2020)

Case report: Strong low-density-cholesterol reduction accompanied by shrinkage of low-attenuation coronary plaque during lipid-lowering treatment with bempedoic acid—serial evaluation by coronary computed tomography angiography
por: Korosoglou, Grigorios, et al.
Publicado: (2023)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
por: Leiter, Lawrence A., et al.
Publicado: (2022)

Bempedoic acid for the treatment of dyslipidemia
por: Marrs, Joel C, et al.
Publicado: (2020)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients
por: Penumarthy, Swati, et al.
Publicado: (2013)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
por: Vallejo‐Vaz, Antonio J., et al.
Publicado: (2018)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
por: Abdalwahab, Ahmed, et al.
Publicado: (2021)

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ihjqprmi0b2hmdrcoct48nob9l